Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
First Claim
1. A method of treating a disease characterized by elevated DLL4 and/or VEGF expression or activity in a subject, comprising administering a binding protein or a pharmaceutical composition comprising the binding protein to a subject in need thereof, wherein the binding protein comprises first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C-(X2)n, whereinVD1 is a first variable domain;
- VD2 is a second variable domain;
C is a constant domain;
X1 is a linker;
X2 is an Fc region;
n is 0 or 1,wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, and wherein the binding protein is capable of binding DLL4 and VEGF, wherein the first polypeptide chain of the binding protein comprises SEQ ID NO;
56 and the second polypeptide chain of the binding protein comprises SEQ ID NO;
64.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
-
Citations
18 Claims
-
1. A method of treating a disease characterized by elevated DLL4 and/or VEGF expression or activity in a subject, comprising administering a binding protein or a pharmaceutical composition comprising the binding protein to a subject in need thereof, wherein the binding protein comprises first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C-(X2)n, wherein
VD1 is a first variable domain; -
VD2 is a second variable domain; C is a constant domain; X1 is a linker; X2 is an Fc region; n is 0 or 1, wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, and wherein the binding protein is capable of binding DLL4 and VEGF, wherein the first polypeptide chain of the binding protein comprises SEQ ID NO;
56 and the second polypeptide chain of the binding protein comprises SEQ ID NO;
64.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
VD2 is a second heavy chain variable domain; C is a heavy chain constant domain; X1 is a linker; X2 is an Fc region; n is 0 or 1, and a second polypeptide chain comprising a second VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first light chain variable domain; VD2 is a second light chain variable domain; C is a light chain constant domain; X1 is a linker; n is 0 or 1 for (X1)n; n is 0 for (X2)n, wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site.
-
-
10. The method of claim 1, wherein the binding protein comprises two first and two second polypeptide chains and four functional target binding sites.
-
11. The method of claim 1, wherein the binding protein is capable of binding:
-
(a) VEGF with a dissociation constant (KD) of at most 7.40×
10−
9M, as measured by surface plasmon resonance; and
/or(b) DLL4 with a dissociation constant (KD) of at most 3.40×
10−
8 M or 5.00×
10−
8 M, as measured by surface plasmon resonance.
-
-
12. The method of claim 1, wherein the Fc region of the binding protein is an Fc region from an IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD, or a variant thereof.
-
13. The method of claim 1, wherein the Fc region of the binding protein is a variant sequence Fc region.
-
14. The method of claim 1, wherein the binding protein comprises the constant region sequences from SEQ ID NO:
- 73 and/or SEQ ID NO;
74.
- 73 and/or SEQ ID NO;
-
15. The method of claim 3, wherein the at least one additional agent comprises one or more of:
- irinotecan, leucovorin, 5-FU, temozolomide, capecitabine, gemcitabine, and paclitaxel.
-
16. The method of claim 3, wherein the at least one additional agent comprises one or more of:
- a cytotoxic agent, a chemotherapeutic agent, an anti-angiogenic agent, an anti-CTLA4 antibody, a calcium channel blocker, an ACE inhibitor, FOLFIRI, paclitaxel, carboplatin, doxil, topotecan, and cisplatin.
-
17. The method of claim 16, wherein the disease is colorectal carcinoma, ovarian cancer, cervical cancer, breast cancer, lung cancer, or pancreatic cancer.
-
18. A method of treating a disease characterized by vascular overgrowth in a subject, comprising administering a binding protein or a pharmaceutical composition comprising the binding protein to a subject in need thereof, wherein the binding protein comprises first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C-(X2)n, wherein
VD1 is a first variable domain; -
VD2 is a second variable domain; C is a constant domain; X1 is a linker; X2 is an Fc region; n is 0 or 1, wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, and wherein the binding protein is capable of binding DLL4 and VEGF, wherein the first polypeptide chain of the binding protein comprises SEQ ID NO;
56 and the second polypeptide chain of the binding protein comprises SEQ ID NO;
64.
-
Specification